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Objectives. The purpose of this study was to examine the 
incidence and implications of recurrent ischemia after different 
reperfusion strategies in acute myocardial infarction. 
Background. The rates and effects of recurrent ischemia after 
reperfusion with thrombolytic therapy and with primary percutane- 
ous transluminal coronary angioplasty have not been compared. 
Methods. At 12 centers 395 patients presenting within 12 h of the 
onset of acute myocardial infarction were prospectively randomized 
to receive recombinant issue-type plasminogen activator (rt-PA) or 
primary coronary angioplasty. Sixteen clinical variables were exam- 
ined by using univariate and multiple logistic regression analysis 
to identify the predictors of recurrent ischemia. The relation of 
recurrent ischemic events to patient outcome was analyzed. 
Results. Recurrent ischemia developed in 76 patients (19.2%) 
before hospital discharge, resulting in reinfarction in 18 patients 
(4.6%) and death in 5 (2.6%). Recurrent ischemia occurred in 56 
patients (28.0%) after rt.PA but in only 20 patients (10.3%) after 
coronary angioplasty (p < 0.0001), directly contributing to a 
higher rate of death or reinfarction (7.5% vs. 3.1%, p = 0.05), 
catheterization and revascularization procedures and prolonged 
hospital stay after thrombolysis. By multivariate analysis, treat- 
ment with coronary angioplasty rather than rt.PA was the stron- 
gest predictor of freedom from recurrent ischemia. Although the 
incidence of recurrent ischemia after angioplasty and after rt-PA 
was similar within the 1st 2 days of admission (9.2% vs. 14.5%, 
p = 0.11), after hospital day 2 recurrent ischemia occurred in only 
2 patients who received primary angioplasty compared with 27 
patients who received rt-PA (1.1% vs. 13.5%, p < 0.0001). 
Conclusions. The development of recurrent ischemia adversely 
affects patient outcome, increasing morbidity, mortality and re- 
source utilization. The much lower rate of recurrent ischemia 
after primary coronary angioplasty than after rt.PA results in 
improved survival without reinfarction and allows a shorter, less 
complicated hospital stay. Given the extremely low rate of recur- 
rent ischemia after hospital day 2, safe early discharge on day 3 
after primary coronary angioplasty should be feasible in selected 
patients with acute myocardial infarction. 
(JAm CoU Cardiol 1995;26:66-72) 
Timely reperfusion i the early hours of evolving acute myo- 
cardial infarction has been shown to reduce mortality and to 
salvage myocardium (1-4). Although thrombolytic therapy is 
widely available and easily administered, a high grade, inher- 
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ently unstable plaque remains in the majority of patients after 
thrombolytic-mediated r perfusion (5,6). As a result, the inci- 
dence of recurrent ischemia and reinfarction is greater in 
patients who receive thrombolysis than in control patients 
treated with placebo (4,5,7-9). Reocclusion of the infarct artery 
after successful reperfusion prolongs the hospital stay, further 
impairs left ventricular performance and decreases survival (6). 
Primary percutaneous transluminal coronary angioplasty 
may be performed inpatients with acute myocardial infarction 
with high success and low rates of morbidity and mortality 
(10-12). Taken together, the results of three well designed 
prospective randomized trials (13-15) comparing primary cor- 
onary angioplasty with thrombolytic therapy followed by con- 
servative care in patients with acute myocardial infarction 
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suggest that primary coronary angioplasty may offer significant 
advantages over thrombolysis, including a reduced rate of 
death and reinfarction, fewer strokes and a shorter hospital 
stay. Furthermore, all three studies howed a markedly lower 
rate of in-hospital recurrent ischemic events after coronary 
angioplasty than after thrombolytic therapy. The extent to 
which the greater freedom from recurrent ischemia after 
angioplasty-mediated r perfusion contributes to the improved 
outcome in these patients has not been examined. 
The results of the Primary Angioplasty in Myocardial 
Infarction (PAMI) trial, in which 395 patients in the early 
phase of acute myocardial infarction were prospectively ran- 
domized to treatment with recombinant tissue-type plasmino- 
gen activator (rt-PA) or primary coronary angioplasty have 
previously been reported (13). The present analysis was un- 
dertaken to identify the incidence and implications of recur- 
rent ischemia after different reperfusion strategies in acute 
myocardial infarction. 
Methods 
Patients of any age presenting with ST segment elevation 
->1 mm in two or more electrocardiographic (ECG) leads with 
ongoing chest pain of <-12 h duration were randomized to 
primary management with rt-PA or primary coronary angio- 
plasty without antecedent thrombolytic therapy at 12 clinical 
sites. Exclusion criteria consisted of the absence of ST segment 
elevation or the presence of left bundle branch block, cardio- 
genie shock and the standard risk factors predisposing to 
increased bleeding risk after thrombolytic therapy (3,16,17). 
Study protocol. On presentation, patients were treated 
with oxygen, 325 mg of chewable aspirin, 10,000 U of intrave- 
nous heparin and intravenous nitroglycerin. Intravenous fol- 
lowed by oral beta-adrenergic blockade was suggested in the 
absence of contraindications. After patients gave informed 
written consent, randomization was performed by opening 
sealed envelopes. As previously described (13), there were no 
significant differences in any baseline characteristics between 
patients randomized to coronary angioplasty or rt-PA. 
Patients assigned to the rt-PA arm received 100 mg (or 
1.25 mg;'kg body weight for patients weighing <65 kg) of rt-PA 
(Activase [Genentech]) over 3 h. After rt-PA infusion, patients 
were treated conservatively according to phase 2B of the 
Thrombolysis in Myocardial Infarction (TIMI) Trial (18). 
However, if ST segment elevation and chest pain persisted 
120 min after initiation of the infusion, arteriography and 
rescue coronary angioplasty, if appropriate, were permitted. 
Patients assigned to the primary coronary angioplasty arm 
underwent emergency arteriography followed by angioplasty, if 
appropriate. Bypass surgery rather than angioplasty was rec- 
ommended for patients with a >70% unprotected left main 
artery stenosis, evere triple-vessel disease but a patent infarct- 
related vessel or morphologic features of the culprit lesion 
known to be unfavorable for angioplasty. Angioplasty was also 
deferred and conservative medical management advised in the 
presence of an occluded infarct-related vessel supplying asmall 
amount of myocardium, a patent infarct-related artery with 
<70% stenosis or inability to identify the culprit lesion. Details 
of the angioplasty procedure have been previously reported 
(13). 
All patients were treated with intravenous nitroglycerin for 
_>24 h followed by oral or topical nitrates, diltiazem and 
aspirin, 325 mg/day. Beta-blockade in the absence of contra- 
indications was encouraged but not required. Intravenous 
heparin was continued for 3 to 5 days, the dose adjusted to 
keep the activated partial thromboplastin me at 1.5 to 2 times 
the control value or the activated clotting time at 160 to 200 s. 
Radionuclide ventriculography was performed within 24 h of 
admission. After initial treatment, unscheduled catheterization 
followed by subsequent revascularization with either coronary 
angioplasty or bypass urgery was allowed for the in-hospital 
recurrence of ischemia, as defined later, or positive findings on 
a predischarge exercise thallium test (13). 
Definitions. All ECGs and angiograms were reviewed in- 
dependently in blinded fashion by a physician and a core 
angiographic laboratory, respectively. Successful angioplasty 
was defined as a residual stenosis <50% with TIMI grade 2 to 
3 flow (19). Recurrent ischemia was predefined in the original 
study protocol as ischemic hest pain lasting >20 min despite 
nitrate therapy with either 1) new ST segment or T wave 
changes, or 2) new onset of pulmonary edema, development of 
a holosystolic murmur or hypotension. Reinfarction was de- 
fined as recurrent chest pain lasting >30 rain with new ST 
segment elevation and either angiographic confirmation of an 
occluded vessel or reelevation of cardiac enzyme levels. 
Data collection and statistical analysis. Clinical data were 
collected prospectively at each of 12 clinical centers by a 
research nurse. After verification by an independent s udy 
monitor, data were entered into a computerized data base. 
Analysis was made on an intention to treat basis. Sixteen 
clinical variables were entered into univariate and multiple 
logistic regression models to identify correlates of in-hospital 
recurrent ischemia and reinfarction. Variables examined in- 
cluded age, gender, presence of diabetes or hypertension, 
cigarette smoking, hypercholesterolemia, previous myocardial 
infarction, previous congestive heart failure, previous bypass 
surgery, infarct location, admission systolic blood pressure, 
admission heart rate, admission Killip classification, time from 
symptom onset o randomization, time from symptom onset o 
treatment, and randomization arm. Categoric variables were 
compared by chi-square analysis. Continuous variables are 
presented as mean value _+ SD and were compared by Student 
t test. All p values are two-tailed. All analyses were performed 
with JMP and Statview statistical software. 
Resu l ts  
Incidence and implications of recurrent ischemia after 
reperfusion. Recurrent ischemia developed in 76 (19.2%) of 
395 patients before hospital discharge, directly resulting in 
reinfarction in 18 patients (4.6%) and death in 5 (2.6%,). 
Significant ST segment or T wave changes were present during 
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Table 1. Implications of Predischarge Recurrent lschemia in 
395 Patients 
Recurrent No Recurrent p 
ln-tlospital Event Ischcmia lschcmia Value 
Patients 7h (24c; , ) 319 (76¢~ l 
Death 5 (~.0%) 13 (4.1c4) (L35 
Reinfarction 18 (23.7 ( , ) 0 (11.0%) <" 0.(1001 
Death or rcinfarction 21 (27.~'V ~ ) 13 (4.1%) <0.0001 
Nonprotocol 57 (75.1V '~ ) 95 (29,8<~) <0.0I)01 
catheterization 
Nonprotocol PT('A 41 (53.9(i) 43 (13.5ci) < 11.[1[!01 
Bypass surgery 18 (23.7~) 22 (6.9c,~) < 0.(][10l 
Nonsustained ventricular 31 (411.8"i) 78 (24.5¢~) 0.1!04 
tachycardia 
Sustained vcntricular 4 (5.3c4) 8 (2.4ci) 0.21 
tachycardia 
Ventricular fibrillation ;~ (78 , )  11 (3.5<~) 0.09 
Atriovenlricular block 9 (1 l.S~i ) 13 (4.1c,: ) 0.1108 
Card;overs;on/defibrillation 8 ( 111.5~ ) 15 (4.7G) 0.{!5 I
Cardiopulmonary 7 (9.2%) 8 (2.4c;) ().i!0(~ 
resuscitation 
Sustained hypotension 1;~ (21. Vi ) 30 (0.4<~) 0.[)04 
Congestive heart failure IS (23.7¢~) 38 (I 1.9%) 0.[108 
Pulmonary edema S ( l l i .5'i ) 6 (1.9!c) 0.{ffl(}2 
lntraaortic balloon pump 9 ( 11.8~i ) 4 (I .2% ) < 0.II00 I
Respirato U failure 7 (9.2%) 12 (3.8C~) 0.04(~ 
Intubation 8 ( lll.5~; ) 10 (3.1% ) 0.11()(~ 
Length of stay (days) 9.(~ - 4.7 7.6 * 3.g 0.{1003 
Hospital charges* $36.659 - $24,774 $28.8~1 + $14,939 0.[!018 
*Includes professional fees, available fl~r 87% of patients. Data arc pre- 
sented as number (q )  of patients or mean value ~ SD. PTCA percutancous 
transluminal coronary angioplasty. 
62 (82%) of these episodes: pulmonary edema was present in 
14 (18%), sustained hypotension in 15 (20%) and a new 
murmur in 7 (9%). Emergency nonprotocol catheterization 
was performed in 57 patients (75%) with recurrent ischemia. 
TIMI grade 0 to 1 flow (reocclusion) was present in the 
infarct-related artery in 21 patients (37%), TIMI grade 2 flow 
in 16 patients (28%) and TIMI grade 3 flow in 20 patients 
(35%). 
Patients who had recurrent ischemia had a considerably 
more complicated hospital course than that of patients without 
recurrent ischemia (Table 1). Patients with recurrent ischemia 
were significantly more likely to experience hemodynamic 
complications of the infarction (including heart failure, hypo- 
tension and requirement for intraaortic balloon counterpulsa- 
tion), respiratory failure requiring intubation, and life- 
threatening arrhythmias and conduction abnormalities 
(ventricular tachycardia nd fibrillation, atrioventricular block 
and cardiac arrest). Recurrent ischemia resulted in a marked 
increase in the need for subsequent cardiac catheterization and 
revascularization procedures (coronary angioplasty and bypass 
surgery). As a result, patients with recurrent ischemia re- 
mained in the hospital a mean of 2 days longer than did 
patients without recurrent ischemia, and they accrued an 
additional $7,800 in hospital charges. 
Recurrent ischemia after primary coronary angioplasty 
and after rt-PA. Recurrent ischemia occurred in 20 patients 
(10.3%) after primary coronary angioplasty compared to 56 
patients (28.0%) after rt-PA (p < 0.0001). Recurrent chest 
pain with associated ST segment or T wave changes occurred 
in 14 patients (7.2%) in the primary' angioplasty arm versus 48 
patients (24.0%) in the rt-PA arm (p < 0.0001). In contrast, 
recurrent chest pain with--alone or in combination--new 
onset pulmonary edema sustained hypotension or the devel- 
opment of a new murmur occurred with similar frequency after 
angioplasty and after rt-PA (5.1% vs. 8.0%, p = 0.25). In 
patients undergoing emergency catheterization for recurrent 
ischemia, reocclusion of the infarct-related vessel was similar 
in patients treated initially with primary coronary angioplasty 
and with rt-PA (40% vs. 36%, p = 0.82). 
As previously reported (13), initial treatment with primary 
coronary angioplasty rather than rt-PA resulted in a reduction 
in the combined rate of death or nonfatal reinfarction (5.1% 
vs. 12.0%, p = 0.015), fewer subsequent unplanned (nonpro- 
tocol) catheterization and coronary angioplasty procedures 
after admission, and a shorter hospital stay. The higher inci- 
dence of recurrent ischemic events after rt-PA than after 
angioplasty contributed to the higher morbidity and resource 
utilization after thrombolysis (Table 2). Specifically, death or 
reinfarction as a result of recurrent ischemia developed in 6 of 
Tab le  2. In-Hospital Outcome in Patients With and Without Recurrent lschemia Stratified by Primary- Treatment 
Patients With Recurrent [schemia Patients Without Recurrent Ischemia 
PTCA rt-PA p PTCA rt-PA p 
in 1951 (n 200) Value (n 195) (n = 20(/) Value 
Patients 211 ( 11L3%: ) 56 (28.0(;) <0,0001 175 (89.7%) 144 (72.0%) <0.0001 
Death I (1!.5~;) 4 (2.1~i) ii,19 4 (2.1%) 9 (4.5%) 0.17 
Nonfatal reinfarction 5 (2.(ici) 13 (t~.5ri) [I.06 (I 0 - -  
Death or reinfarction t~ (3. ](; ) 15 (7.5ci) [!.05 4 (2.1%) 9 (4.5%) 0.17 
Nonprotocol catheterization 10 (5.V;)  47 (22.5~;) U.(RI01 16 (8.2f'~-) 79 (38.5%) <0.0001 
Nonprotocol PTCA 6 (3.1(,; ) 35 (17.5(; ) .- [L(}001 6 (3.1%) 37 (18.5%) <0.0001 
In-hospital bypass surgery' ¢~ (3.1(~) 12 (6.{Ici) {L 16 10 (5.1%) 12 (6.0%) 0.71 
Hospital stay (days) 9.9 + 4.5 9.5 + 4.8 (L89 7.2 + 3.0 8.(1 + 4.5 0.63 
Data arc presented as number (c;) of pat;cuts or mean value + SD. PT('A - pcrcutaneous transluminal coronary., angioplasty: rt-PA recombinant tissue-type 
plasminogen activator. 
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Figure 1. Etiolo~' of death in 395 patients. N - number 
of patients; PTCA - percutaneous transluminal conmary 
angioplasty; t-PA - recombinant tissue-type plasminogen 
activator. 
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the 195 patients treated with angioplasty versus 15 of the 200 
patients treated with rt-PA (3.1gf vs. 7.5%, p - 0.05). A 
breakdown of the cause of death in the PAMI trial is shown in 
Figure 1. The excess mortality after rt-PA versus that after 
angioplasty in the entire study group (6.5% vs. 2.6%, p = 0.06) 
was mostly due to excess cardiac deaths after recurrent isch- 
emia and intracranial bleeding in the rt-PA arm. In addition, 
nonfatal reinfarction as a consequence of recurrent ischcmia 
occurred in 5 patients treated with angioplasty versus 13 
treated with rt-PA (2.6% vs. 6.5%, p = 0.06). 
The 20 patients with recurrent ischemia after corona U
angioplasty required a total hospitalization of 198 days (9.9 _+ 
4.5 clays/patient) in contrast to the 532 days required for the 56 
patients with recurrent ischemia after rt-PA (9.5 + 4.8 days/ 
patient), contributing to the longer stay in the total group 
receiving thrombolysis than in the group undergoing primary 
coronary angioplasty (8.4 _+ 4.6 vs. 7.5 _+ 3.3 days, p - 0.03). 
Correlates of recurrent ischemia (Table 3). By univariate 
analysis, a history of previous myocardial infarction or heart 
failure, presentation with heart failure and treatment with 
rt-PA rather than with coronary angioplasty correlated with 
the development of recurrent ischemia after hospital admis- 
sion. By multiple logistic regression analysis, only treatment 
with rt-PA rather than with coronary, angioplasty and heart 
failure on admission were independently predictive of recur- 
rent ischemia. 
Timing of recurrent ischemia after coronary angioplasty 
versus rt-PA. Although recurrent ischemic events after rt-PA 
occurred with greatest frequency in the 1st 2 days after 
admission, a significant number of patients continued to 
experience recurrent ischemia on days 3 through 7 (Fig. 2). In 
contrast, recurrent ischemic events after primary coronary 
angioplasty rarely occurred after the 2nd hospital day. As 
shown in Figure 3, there was only a weak trend for fewer 
recurrent ischemic events within 2 days of admission in pa- 
tients managed with primary coronary angioplasty versus those 
managed with rt-PA (9.2% vs. 14.5%, p = 0.11). However, 
after the 2rid hospital day, recurrent ischemia occurred in only 
2 patients (1.1%) receiving primary coronary angioplasty in 
contrast o 27 patients (13.5%) receiving rt-PA (p < 0.0001). 
Furthermore, 1 of the 2 patients who had late recurrent 
ischemia after primary coronary, angioplasty was 1 of only 2 
patients in the entire angioplasty arm (n = 195) in whom 
patency was not immediately restored. Thus, of 193 patients in 
the angioplasty arm achieving patency, only 1 (0.5%) had 
recurrent ischemia fter hospital day 2. 
Table 3. Correlates of Recurrent lschemia in 395 Patients 
Recurrent 
Patients Ischemia 
Variable Ino.) {(,~ of patients) 
Adjusted 95% 
Univariate Multivariate Adjusted Confidence 
p Value p VaLue Odds Ratio Intervals 
Randomized to PTCA 195 10.3q 
Randomized to rt-PA 20fl 28.0G 
Admission Killip class 1 339 17.1 ~; 
Admisskm Killip class >2 56 32.1G 
Prior heart failure 6 66.7G 
No prior heart failure 389 18.5q 
Prior myocardial infarction 5S 27.6e; 
No prior myocardial infarction 337 17,8c/ 
< Ii.fl!ll!l <0.0001 1.87 (1.41-2.49) 
li.fllis 0.1126 2.16 (1.10-4.24) 
().llii3 0.07 2.34 (0.934.85) 
0.118 0.25 1.21 (0.85-1.72) 
Abbreviations as in Table 2. 
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Figure 2. Timing of recurrent ischemia after primary coronary 
angioplasty (PTCA) and recombinant tissue-type lasminogen 
activator (t-PA) in 395 patients. N = number of patients. 
Discuss ion  
Implications of recurrent ischemia in acute myocardial 
infarction. After restoration of flow to the infarct-related 
artery in patients with acute myocardial infarction, the devel- 
opment of recurrent ischemia, reinfarction and vessel reocclu- 
sion results in decreased survival and impaired left ventricular 
function (6). This report confirms and extends previous obser- 
vations (20,21) regarding the importance ofrecurrent ischemia 
after reperfusion therapy. Patients who experience recurrent 
ischemia before hospital discharge have a significantly more 
complex hospital course, characterized by frequent hemody- 
namic, respiratory and arrhythmic omplications after an 
initially stable period. Management of recurrent ischemia 
necessitates frequent catheterization a d subsequent revascu- 
larization procedures, prolonging the hospital stay and signif- 
icantly increasing hospital costs. Furthermore, the frequent 
and often unpredictable r currence of unstable ischemia fter 
initially successful reperfusion precludes routine early dis- 
charge after acute myocardial infarction. Thus, the identifica- 
tion and customary use of a reperfusion strategy in which 
recurrent ischemia is relatively uncommon may significantly 
reduce the costs of caring for patients with myocardial infarc- 
tion, as well as improve clinical outcome. 
Figure 3. Incidence of recurrent ischemia before and 48 h after 
hospital admission i patients treated with recombinant tissue-type 
plasminogen activator (t-PA) and primary coronary, angioplasty (PTCA). 
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Recurrent ischemia after primary coronary angioplasty 
versus thrombolysis. Recurrent ischemia is common after 
thrombolytic therapy, occurring more frequently than after 
conservative management without lytic reperfusion (4,5,7-9). 
In contrast, the results of the present study strongly suggest 
that a strategy of primary coronary angioplasty results in a 
striking reduction in the rate of recurrent ischemia ssociated 
with rt-PA therapy (10.3% vs. 28.0%, p < 0.0001). By multiple 
logistic regression analysis, treatment with angioplasty rather 
than rt-PA was the strongest predictor of freedom from 
in-hospital recurrent ischemia. This finding has been con- 
firmed by two other prospective randomized trials (14,15) 
comparing primary coronary angioplasty with thrombolytic 
therapy followed by a conservative care strategy, in which the 
rates of recurrent ischemia ranged from 9% to 15% after 
primary angioplasty in contrast to 36% to 38% after throm- 
bolysis. The lower residual stenosis achieved after angioplasty 
compared to that achieved after thrombolysis (22-24) may 
directly result in a lower incidence of vessel reclosure and 
subsequent ischemia or reinfarction (25,26). 
In contrast o the high rate of recurrent ischemia after 
thrombolysis followed by conservative care, a similar rate of 
recurrent ischemia after primary coronary angioplasty and 
administration of intravenous treptokinase followed by a 
routine 48-h catheterization strategy (8% vs. 10% respectively, 
p = NS) was reported by Ribeiro et al. (27). However, 52% of 
the patients treated with thrombolytic agents in this trial 
underwent predischarge elective angioplasty or bypass urgery 
for the treatment ofhigh grade residual stenoses or multivessel 
disease. Thus, in contrast o the currently recommended 
conservative care approach, a routine invasive strategy after 
thrombolytic therapy may identify patients at risk for recurrent 
ischemia that may be prevented by appropriate r vasculariza- 
tion. 
The lower rate of recurrent ischemia fter coronary angio- 
plasty than after rt-PA contributed to the lower rate of 
reinfarction and death with the invasive strategy, findings 
similar to those of Zijlstra et al. (15) in a study comparing 
primary coronary angioplasty with streptokinase. Ohman et al. 
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(6) found that reinfarction is the second most common cause 
of death after thrombolytic reperfusion. Unplanned predis- 
charge catheterization a d revascularization procedures were 
also much less frequently required for clinical instability result- 
ing from recurrent ischemia fter primary coronary angioplasty 
than after rt-PA (Table 2). However, the requirement for 
nonprotocol catheterization a d revascularization in patients 
without recurrent ischemia was also lower after angioplasty 
than after rt-PA, partly because of the greater freedom from 
exercise-induced ischemia during predischarge treadmill test- 
ing after coronary angioplasty than after rt-PA (13). 
The implications of fewer recurrent ischemic events after 
primary coronary angioplasty than after thrombolysis for a 
shrinking health care budget are evident. By reducing postin- 
farction morbidity, recurrent clinical instability and the need 
for subsequent angiography and intervention, the lower rate of 
recurrent ischemia llowed a shorter hospital stay in patients 
who were treated with primary coronary angioplas~, rather 
than rt-PA. Similarly, the marked isparity in recurrent isch- 
emia in the Mayo Clinic randomized trial (14) contributed toa 
2.9-day mean shorter hospital stay after primary angioplasty 
than after rt-PA (7.7 +_ 2.9 vs. 10.6 + 8.1, p - 0.01), resulting 
in a strong trend toward lower hospital costs after coronary 
angioplasty than after rt-PA ($16,811 vs. $21,400, p = 0.09). 
Implications for early hospital discharge. Early hospital 
discharge (e.g., day 3) after effective reperfusion has the 
potential to further greatly reduce the costs of caring for the 
patient with acute myocardial infarction. This strategy has 
been investigated after thrombolytic therapy, but it is limited 
by the relatively high rate of recurrent ischemia in this setting 
and requires predischarge catheterization r functional testing 
(28,29). In addition, the timing of recurrent ischemia after 
thrombolysis unpredictable; in the present study, although 
14.5% of patients treated with rt-PA had recurrent ischemic 
events within 2 days of admission, 13.5% were in stable 
condition until days 3 to 10. In contrast, recurrent ischemia 
after successful primary coronary angioplasty occurred in only 
one patient (0.5%) after hospital day 2. If these data are 
confirmed by subsequent prospective studies, including the 
ongoing Primary Angioplasty in Myocardial Infarction--lI 
trial, which is testing the feasibility of an early discharge 
strategy after successful primary, coronary angioplasty, the 
majority of patients with successful reperfusion by primary 
coronary angioplasty should be eligible for safe discharge 
within 72 h of admission, further educing health care expen- 
ditures. 
Study limitations. Beta-blockade, which has been shown 
(18) to reduce the incidence of recurrent ischemia nd rein- 
farction after rt-PA, was not mandated in this study. Although 
details regarding drug utilization at the time of each recurrent 
ischemic event are not available, anti-ischemic medications 
appear to have been used equivalently in the coronary angio- 
plasty and rt-PA arms of the study (Table 4). Second, recurrent 
ischemia may be less common after administration f fibrin 
nonselective lytic agents than after administration of rt-PA 
(30). However, the marked reduction in recurrent ischemia 
Table 4. Use of Anti-Ischemic Medications Throughout the Study 
Patients Patients 
With With 
PTCA rt-PA p 
(n = 195) (n = 200) Value 
Beta-blockers 
At time of admission 17 (9%) 23 (12%) 0.36 
In emergency room 31 (16%) 47 (24%) 0.06 
At time of discharge 83 (43%) 84 (42%) 0.91 
Nitrate~, 
At time of admission 25 (13%) 26 (13%) 0.96 
In emergency room 156 (80%) 157 (79%) 0.71 
At time of discharge 100 (51%) 97 (49%) 0.58 
Calcium channel blockers 
At time of admission 32 (16%) 30 (15%) 0.70 
In emergency room 20 (10%) 22 (11%) 0.81 
At time of discharge 83 (43%) 77 (39%) 0.41 
Aspirin 
At time of admission 30 (15%) 28 (14%) 0.70 
In emergency room 169 (87%) 182 (91%) 0.23 
At time of discharge 164 (84%) 169 (85%) 0.91 
Data are presented as number (%) of patients. Abbreviations as in Table 2. 
after primary coronary angioplasty compared with that after 
streptokinase in the Netherlands randomized trial (15) sug- 
gests that the conclusions of the present study may be gener- 
alized to other thrombolytic regimens. 
Conclusions. The development of recurrent ischemia fter 
effective reperfusion of the infarct-related vessel in patients 
with acute myocardial infarction significantly contributes to 
increased patient morbidity, resource utilization, length of 
hospital stay and costs. Compared to thrombolytic therapy 
followed by conservative care, primary coronary angioplasty 
greatly reduces the rate of recurrent ischemic events, thus 
contributing to the improved patient outcome with the invasive 
strategy. The low incidence of recurrent ischemia fter hospital 
day 2 in patients with successful primary coronary angioplasty 
should facilitate safe early discharge without expensive predis- 
charge angiography or exercise testing. 
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